| Name | Title | Contact Details |
|---|
Lutheran Home Care and Hospice is a Chambersburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Established in 1946, OMRF is an independent, nonprofit biomedical research institute with more than 450 staff and over 50 labs studying cancer, heart disease, autoimmune disorders, and diseases of aging. Breakthroughs in our labs have led to three FDA-approved drugs, including the first targeted therapy approved in the U.S. for sickle cell disease and the first approved treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease. OMRF`s critical research is helping people live longer, healthier lives, one discovery at a time. Along the way, OMRF has garnered worldwide media attention, from leading scientific publications like The New England Journal of Medicine and Science to The New York Times and The Wall Street Journal. By pushing the boundaries of biomedical science, our researchers are helping to win the war against human disease, one discovery at a time.
Citicorp Vendor Finance is a Mount Laurel, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Crowne Management is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Monroeville, AL. To find more information about Crowne Management, please visit www.crownemanagement.com
BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.